论文部分内容阅读
BACKGROUND: The availability of novel direct-acting antivirals(DAAs) represents a new era of curative hepatitis C virus(HCV) treatment, with over 95% of patients infected with HCV genotype 1 achieving sustained virological response(SVR). Nevertheless, the